C J van Asperen - JoVE Visualize

Showing results (21-30 of 39) with videos related to

Pageof 4

Sort By:

Clinical Genetics|January 6, 2007

Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective studyI van Oostrom, H Meijers-Heijboer, H J Duivenvoorden, et al.

Archives of Dermatology|June 2, 1998

Restrictive dermopathy. Report of 12 cases. Dutch Task Force on GenodermatologyJ H Smitt, C J van Asperen, C M Niessen, et al.

Breast (Edinburgh, Scotland)|September 18, 2016

Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendeesC M G van Driel, J C Oosterwijk, E J Meijers-Heijboer, et al.

Human Mutation|January 1, 1997

Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1?M H Cnossen, M N van der Est, M H Breuning, et al.

European Journal of Human Genetics : EJHG|August 2, 2003

Possible consequences of applying guidelines to healthy women with a family history of breast cancerC J van Asperen, R A E M Tollenaar, E M M Krol-Warmerdam, et al.

Journal of Medical Genetics|October 7, 2004

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variantG H de Bock, M Schutte, E M M Krol-Warmerdam, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 3, 2006

Association between the CHEK2*1100delC germ line mutation and estrogen receptor statusG H de Bock, M J E Mourits, M Schutte, et al.

Community Genetics|August 28, 2004

Cancer genetics service provision: a comparison of seven European centresP Hopwood, C J van Asperen, G Borreani, et al.

Familial Cancer|February 22, 2015

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.

British Journal of Cancer|August 23, 2025

Capturing breast cancers' copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyondC J H Kramer, L M van Wijk, D Ruano, et al.

Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:

Pageof 4

Clinical Genetics|January 6, 2007

Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective studyI van Oostrom, H Meijers-Heijboer, H J Duivenvoorden, et al.

Archives of Dermatology|June 2, 1998

Restrictive dermopathy. Report of 12 cases. Dutch Task Force on GenodermatologyJ H Smitt, C J van Asperen, C M Niessen, et al.

Breast (Edinburgh, Scotland)|September 18, 2016

Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendeesC M G van Driel, J C Oosterwijk, E J Meijers-Heijboer, et al.

Human Mutation|January 1, 1997

Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1?M H Cnossen, M N van der Est, M H Breuning, et al.

European Journal of Human Genetics : EJHG|August 2, 2003

Possible consequences of applying guidelines to healthy women with a family history of breast cancerC J van Asperen, R A E M Tollenaar, E M M Krol-Warmerdam, et al.

Journal of Medical Genetics|October 7, 2004

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variantG H de Bock, M Schutte, E M M Krol-Warmerdam, et al.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 3, 2006

Association between the CHEK2*1100delC germ line mutation and estrogen receptor statusG H de Bock, M J E Mourits, M Schutte, et al.

Community Genetics|August 28, 2004

Cancer genetics service provision: a comparison of seven European centresP Hopwood, C J van Asperen, G Borreani, et al.

Familial Cancer|February 22, 2015

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.

British Journal of Cancer|August 23, 2025

Capturing breast cancers' copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyondC J H Kramer, L M van Wijk, D Ruano, et al.

Pageof 4